A former Merck director’s Pfizer-backed biotech will take on his old bosses in nascent LILRB field

Only a handful of biotechs are going after LILRBs, components of the innate immune system. But after an initial crop of data out of Merck in autumn 2020, more interest sprung up in the area, and a former Merck franchise director has secured investor backing to try to catch up...

Click to view original post